Considering that the ERK1/2-proliferator-activated receptor α (PPARα) pathway is involved in the modulation of SR-BI expression and cholesterol homeostasis [8], we hypothesized that the recombinant humanized IgG1 antibody might impede dyslipidemia by enhancing hepatic RCT in an FcRn-ERK1/2-PPARα pathway-dependent manner. This evidence concerns the gene MAPK3 and metabolic syndrome.